Tarsus Pharmaceuticals, Inc. (TARS) – What Are Investment Firms Thinking About This Stock?

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been given a consensus recommendation of “Moderate Buy” by the ten analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $100.86.

Several research analysts have recently issued reports on TARS shares. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday. The Goldman Sachs Group assumed coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $116.00 price objective on the stock. Barclays began coverage on shares of Tarsus Pharmaceuticals in a research note on Wednesday, September 16th. They issued an “overweight” rating and a $110.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Finally, Jefferies Financial Group upped their target price on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Elizabeth Lin sold 10,773 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $87.50, for a total value of $942,637.50. Following the transaction, the insider owned 2,547 shares of the company’s stock, valued at approximately $222,862.50. This represents a 80.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total value of $979,750.00. Following the completion of the transaction, the director directly owned 94,487 shares in the company, valued at $7,405,891.06. The trade was a 11.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 48,031 shares of company stock worth $4,004,227 in the last three months. Insiders own 9.64% of the company’s stock.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at about $242,705,000. Jupiter Topco LLC acquired a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at about $176,834,000. Bank of America Corp DE acquired a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at about $75,099,000. TimesSquare Capital Management LLC bought a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at about $23,249,000. Finally, Wasatch Advisors LP acquired a new stake in Tarsus Pharmaceuticals during the second quarter worth approximately $23,198,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Stock Up 1.3%

Shares of NASDAQ TARS opened at $73.16 on Monday. Tarsus Pharmaceuticals has a 12-month low of $53.89 and a 12-month high of $91.53. The firm’s 50-day simple moving average is $74.50 and its 200 day simple moving average is $67.22. The company has a market cap of $3.21 billion, a price-to-earnings ratio of -67.12 and a beta of 0.44. The company has a quick ratio of 3.17, a current ratio of 3.20 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The firm had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. On average, research analysts expect that Tarsus Pharmaceuticals will post -4.25 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company concentrates on areas of significant unmet need in ophthalmology and aims to address conditions that can affect ocular health, comfort and vision.

Tarsus’ primary product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis.